Full TitleOpen Label, Non-Randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Primary CNS Lymphoma
PQR309 is an investigational drug designed to kill cancer cells by inhibiting a protein pathway called PI3K/mTOR. This pathway may be abnormally activated in lymphomas.
In this study, researchers are assessing the safety and effectiveness of PQR309 in patients with primary central nervous system lymphoma that has come back or continued to grow despite treatment. PQR309 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have primary central nervous system lymphoma that has come back or continued to grow despite no more than two prior regimens of treatment.
- Patients may not have previously received an anticancer drug that targets PI3K, mTOR, or AKT.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Christian Grommes at 212-639-4058.